Across TCGA pan-cancer cohorts, TSPYL2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TSPYL2 data layer compared with 23 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher TSPYL2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TSPYL2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

HNSC, UCEC, and KIRC are the cancer types where TSPYL2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.180	0.686	.001	30	view →
UCEC	DFS	Median	All	0.965	0.890	.034	14	view →
KIRC	OS	Median	All	0.196	0.630	.018	10	view →
SKCM	OS	Median	All	0.749	0.326	.018	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: TSPYL2 tumor-vs-normal RNA expression · all TSPYL2 data types